375 related articles for article (PubMed ID: 34670169)
21. Pembrolizumab for the Treatment of Relapsed and Refractory Classical Hodgkin Lymphoma After Autologous Transplant and in Transplant-Naïve Patients.
Halahleh K; Al Sawajneh S; Saleh Y; Shahin O; Abufara A; Ma'koseh M; Abdel-Razeq R; Barakat F; Abdelkhaleq H; Al-Hassan N; Atiyyat R; Al-Faker N; Omari Z; Ghatasheh H; Jaradat I; Muradi I; Iyad S; Bazarbachi A
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):589-595. PubMed ID: 35490153
[TBL] [Abstract][Full Text] [Related]
22. Safety and Efficacy of Consolidation Therapy with Ipilimumab Plus Nivolumab after Autologous Stem Cell Transplantation.
Skarbnik AP; Donato ML; Feinman R; Rowley SD; Vesole DH; Goy AH; Munshi PN; Feldman T; Leslie LA; Biran N; Nyirenda T; Fields PA; Descalzi-Montoya D; Zenreich J; Korngold R; Pecora AL
Transplant Cell Ther; 2021 May; 27(5):391-403. PubMed ID: 33965177
[TBL] [Abstract][Full Text] [Related]
23. Immune Signatures Associated With Clonal Isotype Switch After Autologous Stem Cell Transplantation for Multiple Myeloma.
Ye R; Kundrapu S; Gerson SL; Driscoll JJ; Beck R; Ali N; Landgren O; VanHeeckeren W; Luo G; Kroger N; Caimi P; De Lima M; Malek E
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):e213-e220. PubMed ID: 30878316
[TBL] [Abstract][Full Text] [Related]
24. Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas.
Major A; Kline J; Karrison TG; Fishkin PAS; Kimball AS; Petrich AM; Nattam S; Rao K; Sleckman BG; Cohen K; Besien KV; Rapoport AP; Smith SM
Haematologica; 2022 Jul; 107(7):1608-1618. PubMed ID: 34320785
[TBL] [Abstract][Full Text] [Related]
25. Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma.
Coffey DG; Osman K; Aleman A; Bekri S; Kats S; Dhadwal A; Catamero D; Kim-Schulze S; Gnjatic S; Chari A; Parekh S; Jagannath S; Cho HJ
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38609316
[TBL] [Abstract][Full Text] [Related]
26. Role of Salvage Radiation Treatment of Relapses in Relapsed/Refractory Diffuse Large B Cell Lymphoma Post-Autologous Stem Cell Transplant.
Ladbury C; Kambhampati S; Othman T; Hao C; Chen L; Wong J; Cao T; Herrera A; Mei M; Dandapani S
Int J Radiat Oncol Biol Phys; 2022 Jul; 113(3):594-601. PubMed ID: 35176414
[TBL] [Abstract][Full Text] [Related]
27. Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma.
Liu W; Liu W; Zou H; Chen L; Huang W; Lv R; Xu Y; Liu H; Shi Y; Wang K; Wang Y; Xiong W; Deng S; Yi S; Sui W; Peng G; Ma Y; Wang H; Lv L; Wang J; Wei J; Qiu L; Zheng W; Zou D
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38631712
[TBL] [Abstract][Full Text] [Related]
28. CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma.
Sauter CS; Senechal B; Rivière I; Ni A; Bernal Y; Wang X; Purdon T; Hall M; Singh AN; Szenes VZ; Yoo S; Dogan A; Wang Y; Moskowitz CH; Giralt S; Matasar MJ; Perales MA; Curran KJ; Park J; Sadelain M; Brentjens RJ
Blood; 2019 Aug; 134(7):626-635. PubMed ID: 31262783
[TBL] [Abstract][Full Text] [Related]
29. Case Report: CD19 CAR T-cell therapy following autologous stem cell transplantation: a successful treatment for R/R CD20-negative transformed follicular lymphoma with
Zhang J; Cai D; Gao R; Miao Y; Cui Y; Liu Z; Zhang H; Yan X; Su N
Front Immunol; 2023; 14():1307242. PubMed ID: 38143763
[TBL] [Abstract][Full Text] [Related]
30. An evaluation of pembrolizumab for classical Hodgkin lymphoma.
Manji F; Laister RC; Kuruvilla J
Expert Rev Hematol; 2022 Apr; 15(4):285-293. PubMed ID: 35389317
[TBL] [Abstract][Full Text] [Related]
31. Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma.
Zinzani PL; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; de Oliveira JSR; Buccheri V; Perini GF; Dickinson M; McDonald A; Özcan M; Sekiguchi N; Zhu Y; Raut M; Saretsky TL; Nahar A; Kuruvilla J
Blood Adv; 2022 Jan; 6(2):590-599. PubMed ID: 34644372
[TBL] [Abstract][Full Text] [Related]
32. A Pilot Study of Lenalidomide Maintenance Therapy after Autologous Transplantation in Relapsed or Refractory Classical Hodgkin Lymphoma.
Shea L; Watkins MP; Wan F; Cashen AF; Wagner-Johnston ND; Jacoby MA; Abboud CN; Dipersio JF; Hurd DD; Jaglowski SM; Bartlett NL; Fehniger TA
Biol Blood Marrow Transplant; 2020 Dec; 26(12):2223-2228. PubMed ID: 32829079
[TBL] [Abstract][Full Text] [Related]
33. Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).
Goldkuhle M; Dimaki M; Gartlehner G; Monsef I; Dahm P; Glossmann JP; Engert A; von Tresckow B; Skoetz N
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012556. PubMed ID: 30001476
[TBL] [Abstract][Full Text] [Related]
34. Pembrolizumab in the treatment of refractory primary mediastinal large B-cell lymphoma: safety and efficacy.
Camus V; Bigenwald C; Ribrag V; Lazarovici J; Jardin F; Sarkozy C
Expert Rev Anticancer Ther; 2021 Sep; 21(9):941-956. PubMed ID: 34233557
[No Abstract] [Full Text] [Related]
35. Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation.
Taranto E; Redd R; Jeter E; McHugh K; Crombie JL; Fisher DC; Jacobsen E; Jacobson CA; Kim AI; LaCasce AS; Odejide OO; Dahi PB; Nieto Y; Joyce RM; Chen YB; Bonjoc KC; Chaudhry A; Herrera AF; Armand P; Merryman RW
Leuk Lymphoma; 2022 Dec; 63(12):2912-2917. PubMed ID: 35938581
[TBL] [Abstract][Full Text] [Related]
36. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
37. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
[TBL] [Abstract][Full Text] [Related]
38. Immune Reconstitution Profiling Suggests Antiviral Protection after Transplantation with Omidubicel: A Phase 3 Substudy.
Szabolcs P; Mazor RD; Yackoubov D; Levy S; Stiff P; Rezvani A; Hanna R; Wagner J; Keating A; Lindemans CA; Karras N; McGuirk J; Hamerschlak N; López-Torija I; Sanz G; Valcarcel D; Horwitz ME
Transplant Cell Ther; 2023 Aug; 29(8):517.e1-517.e12. PubMed ID: 37120136
[TBL] [Abstract][Full Text] [Related]
39. A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.
Milgrom SA; Jauhari S; Plastaras JP; Nieto Y; Dabaja BS; Pinnix CC; Smith GL; Allen PK; Lukens JN; Maity A; Oki Y; Fanale MA; Nasta SD
Cancer; 2017 Apr; 123(8):1363-1371. PubMed ID: 27984652
[TBL] [Abstract][Full Text] [Related]
40. Long-term remissions in patients with early relapse of diffuse large B-cell lymphoma following high-dose chemotherapy, autologous stem cell transplantation, and radiotherapy of residual disease.
Metzner B; Welzel J; Müller TH; Casper J; Kimmich C; Petershofen EK; Renzelmann A; Rosien B; Thole R; Voss A; Willborn K; Köhne CH
Strahlenther Onkol; 2022 Jan; 198(1):39-46. PubMed ID: 34735577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
